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Abstract 
Background: There is no consensus on the management of anticoagulation during extracorporeal membrane oxy-
genation (ECMO). ECMO is currently burdened by a high rate of hemostatic complications, possibly associated with 
inadequate monitoring of heparin anticoagulation. This study aims to assess the safety and feasibility of an antico-
agulation protocol for patients undergoing ECMO based on thromboelastography (TEG) as opposed to an activated 
partial thromboplastin time (aPTT)-based protocol.
Methods: We performed a multicenter, randomized, controlled trial in two academic tertiary care centers. Adult 
patients with acute respiratory failure treated with veno-venous ECMO were randomized to manage heparin antico-
agulation using a TEG-based protocol (target 16–24 min of the R parameter, TEG group) or a standard of care aPTT-
based protocol (target 1.5–2 of aPTT ratio, aPTT group). Primary outcomes were safety and feasibility of the study 
protocol.
Results: Forty-two patients were enrolled: 21 were randomized to the TEG group and 21 to the aPTT group. Dura-
tion of ECMO was similar in the two groups (9 (7–16) days in the TEG group and 11 (4–17) days in the aPTT group, 
p = 0.74). Heparin dosing was lower in the TEG group compared to the aPTT group (11.7 (9.5–15.3) IU/kg/h vs. 15.7 
(10.9–21.3) IU/kg/h, respectively, p = 0.03). Safety parameters, assessed as number of hemorrhagic or thrombotic 
events and transfusions given, were not different between the two study groups. As for the feasibility, the TEG-based 
protocol triggered heparin infusion rate adjustments more frequently (p < 0.01) and results were less frequently in the 
target range compared to the aPTT-based protocol (p < 0.001). Number of prescribed TEG or aPTT controls (according 
to study groups) and protocol violations were not different between the study groups.
Conclusions: TEG seems to be safely used to guide anticoagulation management during ECMO. Its use was associ-
ated with the administration of lower heparin doses compared to a standard of care aPTT-based protocol.
Trial registration ClinicalTrials.gov, October 22,2014. Identifier: NCT02271126.
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Background
During extracorporeal membrane oxygenation (ECMO), 
systemic anticoagulation is routinely used to avoid 
thrombin generation due to the contact of blood with 
non-biological surfaces of the extracorporeal cir-
cuit. Despite this, some degree of coagulopathy can be 
detected almost immediately after the start of the extra-
corporeal circulation [1, 2]. This may results in both 
bleeding and thrombotic events, which are the most 
frequent adverse effects during ECMO jeopardizing the 
final outcome [3, 4]: whether hemostasis-related compli-
cations could be attributed to: (1) the underlying patient 
conditions (such as sepsis or inflammation); (2) the effect 
of anticoagulant drugs; or (3) the suboptimal anticoagu-
lation monitoring, is still matter of debate.
So far, we do not have many answers regarding the 
first two issues. Interactions between coagulation, 
inflammation and immune pathways are increas-
ingly recognized but still represent an open field of 
research [5, 6] and unfractionated heparin remains 
the anticoagulant drug of choice in most ECMO cent-
ers [7, 8]. Anticoagulation monitoring methods are 
also far from being ideal [9]. Activated partial throm-
boplastin time (aPTT) is universally recognized as 
the standard assay for monitoring heparin therapy 
[10, 11] and it is considered a good choice in the adult 
population treated with ECMO [7]. However, aPTT is 
performed on plasma samples and may not provide 
a comprehensive picture of the hemostatic profile in 
the absence of the cellular components of the blood. 
In contrast, thromboelastography (TEG) is a whole 
blood viscoelastic point-of-care test, which provides 
information regarding the entire coagulation cascade 
(including platelet function, platelet–fibrin interac-
tions with red blood cells and fibrinolysis). At pre-
sent, TEG has been recommended only to manage 
coagulation abnormalities during ECMO [12]. Nev-
ertheless, the TEG reaction time (the time needed 
to change the physical nature of blood from liquid to 
gel) could act as a surrogate for thrombin generation 
and drive heparin infusion [13–15]. In a retrospective 
study on 32 consecutive patients treated with ECMO 
for severe respiratory failure, we frequently observed 
a marked heparin effect on the TEG tracing despite 
an aPTT ratio and activated clotting time (ACT) 
within the therapeutic anticoagulation range [16]. 
Aware of these findings, since excessive anticoagu-
lation remains a reasonable risk factor for bleeding 
during ECMO [17, 18], we raised the question as to 
whether using a TEG-driven strategy to titrate hepa-
rin during ECMO could represent a safe and feasible 
alternative to the “conventional” approach based on 
aPTT monitoring.
We designed the present pilot study to compare two 
protocols for managing heparin therapy during veno-
venous ECMO: one based on thromboelastography and 
the other based on aPTT ratio, in a population of patient 
with severe respiratory failure.
Methods
Study design
This was a multicenter; prospective, randomized, pilot 
trial performed at two Italian referral ECMO hospitals 
(Fondazione IRCCS Ca’ Granda - Ospedale Maggiore 
Policlinico, Milan; ISMETT Istituto Mediterraneo per i 
Trapianti e Terapie ad Alta Specializzazione, Palermo). 
The study was registered at ClinicalTrials.gov with the 
identifier: NCT02271126. Ethics Committee at both 
participating centers approved the study protocol and 
informed consent was obtained according to Italian 
regulations.
Eligible subjects
Patients requiring ECMO for acute respiratory distress 
syndrome (ARDS) or as a bridge to lung transplant were 
screened for inclusion. Exclusion criteria were veno-arte-
rial ECMO, age < 18 years, heparin-induced thrombocy-
topenia (HIT) or platelet count < 30,000/mm3 and acute 
respiratory failure after lung transplant. The study ended 
at ECMO disconnection, lung transplant (in the case of 
bridge to lung transplant), death of the patient or onset 
of HIT.
ECMO system
Extracorporeal membrane oxygenation was provided 
as femoro-femoral, femoro-jugular or jugular–femoral 
veno-venous bypass. Spring wire-reinforced cannulas for 
both drainage (21–23 Fr, HLS cannulae; MAQUET Car-
diopulmonary AG) and reinfusion (21 Fr, Bio-Medicus 
Venous cannulae, Medtronic Inc.) were inserted percuta-
neously. QUADROX PLS Oxygenator and ROTAFLOW 
Centrifugal Pump or HLS Set Advanced 5.0—Cardiohelp 
system (MAQUET Cardiopulmonary AG, Hirrlingen, 
Germany)—were used. All circuit components, including 
oxygenators, centrifugal pumps and tubings, were BIO-
LINE coated. Membrane lungs were ventilated with an 
oxygen–air blender and maintained at 37 °C with a heat 
exchanger.
Randomization
Patients were randomized in blocks to the aPTT or the 
TEG-based protocol. Randomization was performed cen-
trally, with the use of a computer-generated and blinded 
assignment sequence. Randomization was stratified 
according to the participating ICU and to the reason for 
ECMO connection (ARDS or bridge to lung transplant).
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Study protocol
Before cannulation, blood samples were drawn for base-
line blood chemistry and coagulation parameters. Simul-
taneously a fresh blood sample was also collected to 
measure the baseline thromboelastography  (TEG®, Hae-
monetics, Braintree, MA, USA) profile, using both the 
kaolin reagent to start the coagulation cascade (TEG-K) 
and the kaolin + heparinase reagent to exclude the hepa-
rin effect (TEG-KH).
In both study groups, all patients initially received a 
bolus of unfractionated heparin (70  UI/kg if baseline 
aPTT ratio was < 1.4 or 50 UI/kg if it was ≥ 1.4) followed 
by a continuous heparin infusion (starting at 18 UI/Kg/h) 
to reach a target-activated clotting time (ACT, Hemo-
cron Jr. ® Signature+) between 180 and 210 s. ACT can 
be performed on a portable instrument; thus, it was 
used during the first 12 h in both groups to uniform the 
heparin-guided management in case of transport/cen-
tralization of a patient. After the first 12 h according to 
randomization, the anticoagulation management was 
modified according to the assigned study group: (a) In 
the TEG group (intervention group), heparin infusion 
was titrated to reach a target TEG-K reaction time (R-K) 
of 16–24  min (normal values: 4–8  min) and (b) in the 
aPTT group (standard of care–control group), heparin 
infusion was titrated to reach a target aPTT ratio value 
of 1.5–2. In both groups, heparin infusion rate was then 
adjusted according to a predefined algorithm (Fig. 1) by 
using only TEG or aPTT, respectively. In case of a “flat-
line” TEG (i.e., a TEG tracing unable to generate a R-K 
parameter without heparinase within 90  min), R-K was 
censored at 90 min. To study the correlation between R-K 
and aPTT, in the TEG group one single aPTT value was 
obtained in the morning; similarly, one single determi-
nation of R-K was obtained every morning in the aPTT 
group. In case of surgery, minimal levels of anticoagula-
tion (i.e., R-K of 8–12 min and aPTT ratio of 1.2–1.3, in 
the study and control group, respectively) were tolerated 
during the first 24 h after the operation. In case of bleed-
ing heparin infusion was reduced to the lower value of 
the target range or interrupted based on the severity of 
bleeding. Heparin dose was never increased in the TEG 
group if the corresponding aPTT was 2.5 or higher.
Every violation of the study protocol was recorded. 
Violations were classified as:
  • minor violations: inadvertent violations and signifi-
cant (> 4 h) delays in TEG or aPTT analysis
  • major violations: intentional violations by the medi-
cal staff for clinical reasons.
Hemoglobin concentration, platelet count, prothrom-
bin time (PT) (patient-to-normal) ratio, fibrinogen and 
D-dimer level were determined every 8 h in all patients. 
Free hemoglobin level, haptoglobin, antithrombin and 
anti-factor Xa activity (anti-Xa) were measured once 
daily in all patients. Packed red blood cells, fresh frozen 
plasma and platelets were transfused to maintain hemo-
globin concentration > 10 g/dL, PT ratio < 1.5 and platelet 
count > 45,000/mm3. Fibrinogen and antithrombin were 
supplemented to maintain fibrinogen levels > 150 mg/dL 
and antithrombin activity > 70%. Transfused blood prod-
ucts were registered every day as well as the total amount 
of heparin infused to each patient (including boluses and 
holding of the infusion).
ECMO circuit (including the artificial lung) function 
was regularly assessed with a dedicated score (circuit 
change score, Additional file 1: Table E1). Circuit change 
was performed when the circuit change score was  >  5 
and there was evidence of bleeding from any site (Addi-
tional file 1: Figure E1).
Outcomes
Primary outcomes of the study were:
Fig. 1 During the first 12 h after ECMO cannulation, the algorithm 
was identical in the two study groups. After the first 12 h according 
to randomization, the anticoagulation management was modified 
according to the assigned study group: In the TEG group (interven-
tion group), heparin infusion was titrated to reach a target TEG-K 
reaction time (R-K) of 16–24 min (normal values: 4–8 min); in the aPTT 
group (standard of care–control group), heparin infusion was titrated 
to reach a target aPTT ratio value of 1.5–2. Under-target levels of anti-
coagulation were corrected with either heparin bolus plus increase in 
infusion or with increase in infusion only; similarly, over-target levels 
of anticoagulation were corrected with either heparin infusion stop 
for 30 or 60 min and restart with a reduced dose or with decrease in 
infusion only. Time to the next control varied according to the degree 
of derangement from target values of anticoagulation. In case of sur-
gery, minimal levels of anticoagulation (i.e., R-K of 8–12 min and aPTT 
ratio of 1.2–1.3, in the study and control group, respectively) were 
tolerated during the first 24 h after the operation. In case of bleeding, 
heparin infusion was reduced to the lower value of the target range 
or interrupted based on the severity of bleeding
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(1) Safety of the study protocol: number of hemorrhagic 
or thrombotic events and blood product transfusions.
Bleeding was regularly assessed using a checklist of 
potential bleeding sites. We also standardized severity of 
bleeding using five categories adjusted from the Bleeding 
Academic Research Consortium score [19]:
  • Type 0: No bleeding;
  • Type 1: Any overt bleeding that requires heparin 
infusion rate reduction or packed red blood cells 
transfusion (provided hemoglobin drop was related 
to bleeding);
  • Type 2: Any overt bleeding that requires heparin 
infusion rate reduction and packed red blood cells 
transfusion (provided hemoglobin drop was related 
to bleeding);
  • Type 3: Any life-threatening bleeding that required 
packed red blood cells transfusion and surgical inter-
vention for control of bleeding or ECMO discontinu-
ation;
  • Type 4: Any fatal bleeding.
Any objective sign of patient’s thrombosis was reported 
everyday at daily visit. The extracorporeal circuit and 
the ECMO oxygenator were inspected three times a day 
in order to detect visible clots. Within 24 h after ECMO 
removal, a Doppler ultrasonography of the cannulated 
vessels and of the vena cava was performed to exclude 
thrombosis due to vascular cannulation.
(2) Feasibility of the study protocol: number of heparin 
dose adjustments, number of prescribed analyses, 
number of R-K or aPTT ratio (according to groups) 
results within the target range and number of study 
protocol violations.
Secondary outcomes were number of ECMO circuit 
failures/changes, over-anticoagulation (expressed as the 
proportion of flat-line TEG) and correlation between 
heparin dose and aPTT or R-K in the two groups.
Finally, we performed a cost analysis, to compare the 
expenses for monitoring tests execution and heparin 
infusion between the study groups.
Statistical analysis
Given the nature of this study (pilot), a sample size of 
12 patients per group is considered sufficient [20]. To 
increase power, we foresaw to enroll at least 20 patients 
per group. Continuous variables are reported as median 
and 25th and 75th percentile. Categorical variables are 
presented as absolute and relative frequencies. Wil-
coxon rank-sum tests and Fisher’s exact test were used 
to analyze continuous and categorical variables, respec-
tively. Correlations between heparin dose and monitoring 
methods were expressed using the Spearman correlation 
coefficient. To compare blood and coagulation parame-
ters in the two groups during the study period, we used 
random intercept models because the outcomes were 
repeated within subjects [21]. We used a multinomial 
logistic regression model to calculate the association 
between the proportion of aPTT and R-K within target 
range in the two study groups. All tests were two-sided. 
Stata 13.1 was used for analyses (StataCorp, College Sta-
tion, TX, USA).
Results
Between September 2, 2014, and November 30, 2016, we 
screened 64 patients; of these, 42 were enrolled (21 in the 
TEG group and 21 in the aPTT group). (In Fig. 2 reasons 
for exclusion of the remaining patients are depicted.) 
Baseline clinical characteristics and coagulation param-
eters of the patients are summarized in Table  1. There 
appeared to be a degree of imbalance only in the propor-
tion of women enrolled in the two groups. There was no 
difference in baseline coagulation parameters; only one 
patient for each group presented with DIC at study entry. 
C-reactive protein was not different in the two groups at 
study entry: 16.2 (8.2–24.1) mg/dL in the TEG group and 
14.5 (6.7–25.2) mg/dL in the aPTT group, p = 0.63.
Table 2 shows blood and coagulation parameters dur-
ing the study period. Heparin infusion rate, aPTT ratio, 
R-K and anti-Xa were lower in the TEG group compared 
to the aPTT group.
Duration of ECMO was comparable between the two 
groups: 9 (7–16) days in the TEG group and 11 (4–17) 
days in the aPTT group, p = 0.74.
Fig. 2 Flow diagram. We assessed 64 patients for eligibility. Of these, 
patients 22 were excluded. We enrolled and randomly assigned 
the remaining 42 to the aPTT or TEG arm. Thirty-one patients were 
enrolled in the Fondazione Ca’ Granda (Milan, Italy) center and 11 
patients in the ISMETT (Palermo, Italy) center
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Safety outcomes
Hemorrhagic and thrombotic complications are reported 
in Table  3. Although not significantly, patients in the 
aPTT group tended to bleed more compared to the 
TEG group (15 vs. 10, respectively, p =  0.21) especially 
in surgical sites (including bleeding from tracheostomy) 
(p  =  0.02). The most frequent hemorrhagic complica-
tion was mucosal bleeding in both groups. None of the 
patients experienced intracranial bleeding. Severity of 
bleeding episodes was not different between the two 
groups (p  =  0.62). Most of the patients were classified 
with a “bleed type  =  0” (9 vs. 11 patients in the aPTT 
and TEG group, respectively), and 4 patients were classi-
fied with a bleed type ≥ 3 in the aPTT group and 1 in the 
TEG group.
Four patients in both groups experienced thrombotic 
complications, without differences in specific sites of 
thrombosis. The most frequent thrombotic complication 
was deep venous thrombosis related to the presence of 
the ECMO cannula in both groups. D-dimer was not dif-
ferent in the two groups during the study time (p = 0.95) 
(Additional file 1: Table E2).
Transfusions of blood products were not different in 
the study groups.
Feasibility outcomes
TEG results triggered a heparin infusion rate change 
more frequently than aPTT results (0.58 (0.53–0.71) 
vs. 0.40 (0.30–0.53) heparin rate changes per analysis, 
respectively, p = 0.01). The number of TEG or aPTT con-
trols (according to study groups) to each patient per day 
was not different in the two groups [3.2 (2.8–3.4) TEG 
analyses in the TEG group compared to 3 (2.9–3.3) aPTT 
analyses in the aPTT group (p = 0.88)]. Analyses were in 
the target range (i.e., R-K 16–24 min for the TEG group 
and aPTT ratio 1.5–2 for the aPTT group) more fre-
quently in the aPTT group compared to the TEG group, 
56.5 and 29.8% of the times, respectively (p < 0.001). In 
the latter group, R-K values were more frequently close 
or above the upper limit of the target values (Fig. 3).
Major violations to the protocols algorithms were [0 
(0–0.1) per patient per day in each group and 0.1 (0–0.2) 
and 0 (0–0.2) minor violations in the TEG and aPTT 
groups, respectively (p = 0.52)].
Secondary outcomes
The ECMO circuit was never exchanged in the vast 
majority of patients in both study groups (0 (0–1) and 
0 (0–0) circuit per patient in the TEG and aPTT group, 
Table 1 Characteristics of the patients and baseline coagulation parameters
Data are reported as median (25th–75th percentile) or as absolute and relative frequencies as appropriate
BMI body mass index, ARDS acute respiratory distress syndrome, SOFA sepsis-related organ failure assessment, PT prothrombin time, DIC disseminated intravascular 
coagulation, ICU intensive care unit
*From Wilcoxon rank-sum (continuous variables) or Fisher’s exact (categorical variables) test
°ISTH criteria (Taylor, FB et al. Thromb Haemost. 2001). DIC patients: #4 (aPTT group) and #30 (TEG group)
Characteristics of the patients TEG group (N = 21) aPTT group (N = 21) P value*
Age (years) 43 (36–53) 48 (40–58) 0.24
Female sex, N (%) 13 (62) 5 (24) 0.03
BMI (kg/m2) 21.8 (20.8–26.1) 27.7 (21.2–29.4) 0.11
ECMO duration (days) 9 (7–16) 11 (4–17) 0.74
Cause of respiratory failure 0.73
 ARDS, N (%) 14 (66.7) 16 (76.2)
 Bridge to lung transplant, N (%) 6 (28.6) 5 (23.8)
 Status asthmaticus, N (%) 1 (4.8) 0
Renal replacement therapy, N (%) 4 (19) 7 (33) 0.48
SOFA 7 (5–10) 9 (6–11) 0.54
ICU mortality, N (%) 4 (19) 6 (29) 0.72
Hospital mortality, N (%) 4 (19) 6 (29) 0.72
Baseline coagulation parameters
 Platelet count (*109/L) 185 (81–205) 154 (109–268) 0.77
 Hemoglobin (g/L) 10.6 (9–11.1) 11.2 (9.8–12.3) 0.09
 Creatinine (mg/dL) 0.9 (0.4–1.0) 1.1 (08.1.62) 0.20
 Fibrinogen (mg/dL) 520 (350–626) 476 (357–573) 0.77
 PT (ratio) 1.3 (1.2–1.4) 1.3 (1.1–1.5) 0.87
 DIC°, N (%) 1 (4.8) 1 (4.8) 0.76
 DIC score° 1 (1–3) 3 (2–3) 0.33
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respectively, p  =  0.82). There was no difference in the 
circuit change score between the two study groups 
either (4 (1–5), max 13, in the TEG group and 3 (1–5), 
max 8, in the aPTT group, p = 0.35). The proportion of 
flat-line TEG results was lower in the TEG group com-
pared to the aPTT group (4.7 vs. 37.7%, p  <  0.001). In 
both study groups, heparin dose was neither correlated 
with R-K (Spearman’s rho = 0.16, p = 0.29 from random 
intercept model) nor with aPTT (Spearman’s rho = 0.23, 
p = 0.46 from random intercept model). R-K was signifi-
cantly and moderately correlated with anti-Xa only when 
anti-Xa was below the anticoagulant range (< 0.3 IU/mL) 
(Spearman’s rho = 0.53, p = 0.01 from random intercept 
model). The median anti-Xa of flat-line TEG tracings was 
0.36 (0.26–0.41) IU/mL.
Following the TEG algorithm was more expensive 
than following the aPTT algorithm [26.28 (23.86–28.36) 
€ vs. 8.70 (8.53–9.49) € per patient per day, respectively, 
p  <  0.001]. The use of the TEG algorithm resulted in a 
lower expense for heparin (3.97 (2.78–5.20) € vs. 6.79 
(5.18–7.98) € per patient per day, respectively, p < 0.001).
Discussion
In our pilot study, an anticoagulation managing strategy 
based on a thromboelastography-derived parameter, R 
time, seems to be as safe as the “conventional” strategy 
based on aPTT ratio monitoring. Moreover, although 
there was no (statistically significant) difference in hem-
orrhagic complications and blood product transfusions 
between the two study groups, we observed a tendency 
for less bleeding in the TEG group, with no difference in 
thrombosis. We also observed a lower incidence of bleed-
ing from surgical sites in the TEG group.
As for the feasibility, the number of protocol violations 
was small in both groups, indicating that the algorithm 
was easy to follow. Interestingly, the number of analyses 
in the target range was lower in the TEG group, resulting 
in a higher number of heparin dosing adjustments. This 
may be explained by the sensitivity of TEG (even in the 
early phases of clot formation) to low heparin dosing [11] 
and to fibrinogen and platelet levels [22].
As expected from previous research [16], our TEG-
based protocol resulted in the prescription of a much 
lower amount of heparin, even inferior to usual prophy-
lactic doses. This was confirmed by significantly lower 
values in the TEG group of anti-Xa activity, which is con-
sidered the gold standard assay to measure heparin effect; 
importantly, in our study this test was performed without 
adding antithrombin to the plasma sample. It must be 
noted, however, that anti-Xa values were at the lower end 
of the recommended level for proper anticoagulation [12, 
23] even in the aPTT group. Nevertheless, the number of 
thrombotic episodes was small and not different between 
the study groups.
Since this was the first time a TEG-based protocol was 
used to adjust heparin infusion, we planned a safety rule 
of not increasing heparin dose in the TEG group if the 
corresponding aPTT was 2.5 or higher. Yet, this never 
happened.
One of the major concerns of using a low level of anti-
coagulation during ECMO is the development of con-
sumptive coagulopathy [1, 24]; this was not the case 
since D-dimer levels were comparable in the two groups. 
Importantly, we tried to standardize the timing of cir-
cuit exchange by means of daily calculation of a “circuit 
change score” based on coagulation alterations, heparin 
requirements, visual evaluation of clotting in the system 
and functional ECMO parameters. This score together 
with the evidence of clinically relevant coagulation altera-
tions (i.e., bleeding), prompted the decisions to exchange 
the circuit. This may have prevented the development of 
Table 2 Blood parameters, coagulation parameters 
and anticoagulation in  the t wo gr oups during  the study 
period
Data are reported as median (25th–75th percentile) or as absolute and relative 
frequencies as appropriate
Heparin and antithrombin were administered i.v. as continuous infusion
N number of measurements, PT prothrombin time, aPTT activated partial 
thromboplastin time, CRP C-reactive protein
*From random intercept linear regression models
§ The amount of heparin infused to each patient was calculated as the total 
administered heparin per kg of body weight (including boluses) divided by the 
total hours of heparin infusion. P value from Wilcoxon rank-sum test
°R-K was arbitrarily considered equal to 90 if unable to generate a value within 
90 min (flat-line)





Hemoglobin (g/dL) 10.0 (9.5–10.6) 10.2 (9.7–10.8) 0.25
Hematocrit (%) 30.5 (28.5–31.9) 30.8 (29.0–32.4) 0.47
Platelet count 
(*109/L)
118.0 (72–202) 122 (88–172) 0.78
Creatinine (mg/dL) 0.6 (0.4–1.1) 1.0 (0.8–1.3) 0.14
Heparin§ (IU/kg/h) 11.7 (9.5–15.3) 15.7 (10.9–21.3) 0.03
aPTT (ratio) 1.2 (1.1–1.6) 1.6 (1.4–1.8) < 0.001
R-K° (min) 18.8 (12.9–27.4) 61.9 (32.7–90.0) < 0.001
Flat-line TEG, N (%) 34 (4.7) 52 (37.7) < 0.001
R-KH (min) 6.2 (5.2–7.6) 8.1 (6.8–9.9) 0.50
Anti-Xa (IU/mL) 0.1 (0.1–0.2) 0.3 (0.2–0.4) < 0.001
PT (ratio) 1.1 (1.1–1.3) 1.2 (1.1–1.3) 0.69
Antithrombin (%) 90.0 (71.0–103.0) 77.0 (64.0–91.0) 0.15
Antithrombin (IU/
die)
1000 (0–2000) 2000 (2000–2000) 0.17
Fibrinogen (mg/dL) 391.5 (275.0–524.5) 466.0 (327.0–611.0) 0.96
Free hemoglobin 
(mg/dL)
8.5 (6.7–10.4) 9.1 (7.0–12.7) 0.50
CRP (mg/dL) 12.5 (7.6–23.0) 15.3 (7.8–23.2) 0.52
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Table 3 Hemorrhagic and thrombotic complications
Data are reported as median (25th–75th percentile) or as absolute and relative frequencies as appropriate
CNS central nervous system, ECMO extracorporeal membrane oxygenation, RBC red blood cells, FFP fresh frozen plasma
# A patient could have more than one site of bleeding
§ Categories of bleeding according to Mehran et al. [18]
*From Wilcoxon rank-sum (continuous variables) or Fisher’s exact (categorical variables) test
Complications TEG group (N = 21) aPTT group (N = 21) P value*
Patients with any bleeding, N (%) 10 (47.6) 15 (71.4) 0.21
Site of  bleeding#, N (%)
 CNS 0 (0) 0 (0) –
 Gastrointestinal tract 3 (14.3) 1 (4.8) 0.61
 Vascular catheters insertion site 4 (19.0) 7 (33.3) 0.48
 ECMO cannula insertion site 5 (23.8) 5 (23.8) 1.0
 Mucosal bleeding (oral, nasal, airways) 6 (28.6) 10 (47.6) 0.34
 Surgical site (including tracheostomy) 0 (0) 6 (28.6) 0.02
 Urinary tract 2 (9.5) 5 (23.8) 0.41
Severity of bleeding (bleed type) 0.46
 Type 0, N (%) 11 (52.38) 9 (42.86)
 Type 1, N (%) 1 (4.76) 3 (14.29)
 Type 2, N (%) 8 (38.10) 5 (23.81)
 Type 3, N (%) 1 (4.76) 3 (14.29)
 Type 4, N (%) 0 (0.00) 1 (4.76)
Patients with any thrombosis, N (%) 4 (19.0) 4 (19.0) 1.0
Site of thrombosis, N (%)
Deep venous thrombosis (ECMO cannula-related) 2 (9.5) 3 (14.3) 1.0
Vascular catheter-related thrombosis 1 (4.8) 1 (4.8) 1.0
ECMO cannula occlusion 1 (4.8) 0 1.0
RBC transfused (ml/day/patient) 198 (37–330) 203 (155–247) 0.74
FFP transfused (ml/day/patient) 0 (0–79) 0 (0–0) 0.54
Platelet transfused (ml/day/patient) 0 (0–61) 0 (0–0) 0.28
Fig. 3 aPTT ratio and R-K values during study days in patients randomized to the aPTT group (panel A) and to the TEG group (panel B). Lines are 
lowess smoothing. Reference lines: 1.5–2 for the aPTT ratio and 16–24 min for the R time. 56.5% of the analysis was in range in the aPTT group com-
pared to 29.8% in the TEG group (p < 0.001). aPTT activated partial thromboplastin time ratio, R-K TEG reaction time, TEG thromboelastography
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a severe form of coagulopathy. However, score values and 
the number of exchanged ECMO system were similar in 
the two groups.
Since excessive anticoagulation increases the risk of 
bleeding during ECMO [17] and advances in technol-
ogy (i.e., circuit coating with biocompatible surfaces) 
are supposed to reduce the incidence of circuit throm-
bosis, several reports of minimal anticoagulation during 
ECMO have been published. In a retrospective study by 
Agerstrand et al., incidence of bleeding was reduced and 
circuit or oxygenator thrombosis was rare, using a low 
target aPTT [25]. Yeo et al. described a lower incidence 
of bleeding and blood products transfusions in patients 
anticoagulated according to a lower than conventional 
ACT target [26]. Recently, Krueger et  al. reported that 
a prophylactic regimen with only subcutaneous enoxa-
parin was feasible and safe in 61 patients on veno-
venous ECMO [27]. Anyhow, due to the high variability 
in patients’ response to heparin [28], we believe in the 
added value of monitoring anticoagulation also when low 
levels of heparin are used. In our study, we confirmed that 
R-K is sensitive to low doses of heparin, but it loses accu-
racy at recommended anticoagulant ranges (i.e., anti-Xa 
0.3–0.7  IU/mL) [23, 29]. Interestingly, the frequency of 
flat-line TEG tracings was lower in this study compared 
to our previous experiences [16]. This may be explained 
by a strict and prospective adherence to the protocol for 
heparin adjustment, which was not the case in our previ-
ous retrospective study.
Since the anticoagulant effect of heparin is medi-
ated mainly by antithrombin [10], we supplemented 
antithrombin to achieve an activity level above 70%. We 
observed a tendency for lower antithrombin levels in the 
aPTT group, probably explained by increased consump-
tion mediated by higher administered heparin dose.
Our study revealed that the use of TEG resulted in a 
higher costs compared to the aPTT group. Performing a 
TEG in fact is more expensive than requesting an aPTT 
from the laboratory, at least in the two facilities where 
the study was conducted. Notwithstanding, this was bal-
anced in part by the lower expenses for the anticoagulant.
Our study has several limitations. First, it is a pilot 
study on a relatively small number of patients. Second, 
the target ranges for anticoagulation applied in both 
groups were arbitrarily chosen. Indeed, anticoagulation 
targets are different between ECMO centers [8]. We used 
an aPTT range between 1.5 and 2 times control, which 
is considered adequate in other settings [28] [30, 31] 
and that was common practice in the two participating 
institutions; however, it has never been validated dur-
ing ECMO. Likewise the target R-K time of 16–24  min 
(equivalent to 2–3 times the upper limit of normal values) 
had not been validated before. Both of them may require 
to be better defined. Third, the use of FFP and antithrom-
bin, the target hemoglobin, fibrinogen and platelets is not 
standard across centers. Hence, the results of our study 
might have also been influenced by the contributions of 
these variables.
Conclusions
We found that using a TEG-driven protocol seems to 
be feasible to manage heparin anticoagulation during 
VV-ECMO and does not look to be associated with an 
increased rate of complications. Furthermore, even if 
our study was not powered to detect major differences in 
outcomes, the TEG protocol allowed the administration 
of lower heparin doses without an increase in thrombotic 
complications and with a tendency for less bleeding com-
pared to the aPTT protocol. A larger trial is warranted to 
confirm these preliminary findings.
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